Loading clinical trials...
Loading clinical trials...
An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase® in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
Conditions
Interventions
Idursulfase-IT
Elaprase
Locations
9
United States
Ann & Robert H Lurie Childrens Hospital of Chicago
Chicago, Illinois, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Legacy Emanuel Hospital
Portland, Oregon, United States
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, United States
Vanderbilt Children's Hospital
Nashville, Tennessee, United States
University of Utah Hospital
Salt Lake City, Utah, United States
Start Date
August 1, 2010
Primary Completion Date
April 30, 2024
Completion Date
April 30, 2024
Last Updated
August 6, 2025
NCT05422482
NCT05795361
NCT02412787
NCT05058391
NCT03920540
NCT03582449
Lead Sponsor
Takeda
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions